Literature DB >> 25783759

Sequential monitoring and stability of ex vivo-expanded autologous and nonautologous regulatory T cells following infusion in nonhuman primates.

H Zhang1, H Guo, L Lu, A F Zahorchak, R W Wiseman, G Raimondi, D K C Cooper, M B Ezzelarab, A W Thomson.   

Abstract

Ex vivo-expanded cynomolgus monkey CD4(+)CD25(+)CD127(-) regulatory T cells (Treg) maintained Foxp3 demethylation status at the Treg-specific demethylation region, and potently suppressed T cell proliferation through three rounds of expansion. When carboxyfluorescein succinimidyl ester- or violet proliferation dye 450-labeled autologous (auto) and nonautologous (non-auto)-expanded Treg were infused into monkeys, the number of labeled auto-Treg in peripheral blood declined rapidly during the first week, but persisted at low levels in both normal and anti-thymocyte globulin plus rapamycin-treated (immunosuppressed; IS) animals for at least 3 weeks. By contrast, MHC-mismatched non-auto-Treg could not be detected in normal monkey blood or in blood of two out of the three IS monkeys by day 6 postinfusion. They were also more difficult to detect than auto-Treg in peripheral lymphoid tissue. Both auto- and non-auto-Treg maintained Ki67 expression early after infusion. Sequential monitoring revealed that adoptively transferred auto-Treg maintained similarly high levels of Foxp3 and CD25 and low CD127 compared with endogenous Treg, although Foxp3 staining diminished over time in these nontransplanted recipients. Thus, infused ex vivo-expanded auto-Treg persist longer than MHC-mismatched non-auto-Treg in blood of nonhuman primates and can be detected in secondary lymphoid tissue. Host lymphodepletion and rapamycin administration did not consistently prolong the persistence of non-auto-Treg in these sites. © Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  Immunosuppressant; T cell biology; animal models: nonhuman primate; basic (laboratory) research / science; immunobiology; immunosuppressant; immunosuppression / immune modulation; mechanistic target of rapamycin (mTOR); polyclonal preparations: rabbit antithymocyte globulin; translational research / science

Mesh:

Substances:

Year:  2015        PMID: 25783759      PMCID: PMC4773915          DOI: 10.1111/ajt.13113

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  71 in total

1.  CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs.

Authors:  R Förster; A Schubel; D Breitfeld; E Kremmer; I Renner-Müller; E Wolf; M Lipp
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

2.  Promotion of allograft survival by CD4+CD25+ regulatory T cells: evidence for in vivo inhibition of effector cell proliferation.

Authors:  Major K Lee; Daniel J Moore; Beth P Jarrett; Moh Moh Lian; Shaoping Deng; Xiaolun Huang; Joseph W Markmann; Meredith Chiaccio; Clyde F Barker; Andrew J Caton; James F Markmann
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

3.  In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures.

Authors:  Wayne R Godfrey; Ying G Ge; Darrin J Spoden; Bruce L Levine; Carl H June; Bruce R Blazar; Stephen B Porter
Journal:  Blood       Date:  2004-03-18       Impact factor: 22.113

4.  Induction of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes.

Authors:  Olivier Joffre; Nathalie Gorsse; Paola Romagnoli; Denis Hudrisier; Joost P M van Meerwijk
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

5.  Tolerance induction by third-party "off-the-shelf" CD4+CD25+ Treg cells.

Authors:  David Steiner; Noga Brunicki; Bruce R Blazar; Esther Bachar-Lustig; Yair Reisner
Journal:  Exp Hematol       Date:  2006-01       Impact factor: 3.084

6.  NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145.

Authors:  Sanja Vodanovic-Jankovic; Parameswaran Hari; Paulette Jacobs; Richard Komorowski; William R Drobyski
Journal:  Blood       Date:  2005-09-20       Impact factor: 22.113

7.  Renal allograft rejection is prevented by adoptive transfer of anergic T cells in nonhuman primates.

Authors:  Hisashi Bashuda; Masaaki Kimikawa; Kenichiro Seino; Yojiro Kato; Fumiko Ono; Akira Shimizu; Hideo Yagita; Satoshi Teraoka; Ko Okumura
Journal:  J Clin Invest       Date:  2005-06-09       Impact factor: 14.808

8.  Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood.

Authors:  H Jonuleit; E Schmitt; M Stassen; A Tuettenberg; J Knop; A H Enk
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

9.  Molecular mechanisms of lymphocyte homing to peripheral lymph nodes.

Authors:  R A Warnock; S Askari; E C Butcher; U H von Andrian
Journal:  J Exp Med       Date:  1998-01-19       Impact factor: 14.307

10.  In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes.

Authors:  Qizhi Tang; Kammi J Henriksen; Mingying Bi; Erik B Finger; Greg Szot; Jianqin Ye; Emma L Masteller; Hugh McDevitt; Mark Bonyhadi; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2004-06-07       Impact factor: 14.307

View more
  18 in total

Review 1.  Methods to manufacture regulatory T cells for cell therapy.

Authors:  K N MacDonald; J M Piret; M K Levings
Journal:  Clin Exp Immunol       Date:  2019-04-15       Impact factor: 4.330

2.  Adoptive Cell Therapy with Tregs to Improve Transplant Outcomes: The Promise and the Stumbling Blocks.

Authors:  Mohamed B Ezzelarab; Angus W Thomson
Journal:  Curr Transplant Rep       Date:  2016-10-25

Review 3.  Promises and limitations of immune cell-based therapies in neurological disorders.

Authors:  Xiaoming Hu; Rehana K Leak; Angus W Thomson; Fang Yu; Yuguo Xia; Lawrence R Wechsler; Jun Chen
Journal:  Nat Rev Neurol       Date:  2018-09       Impact factor: 42.937

Review 4.  Transplant trials with Tregs: perils and promises.

Authors:  Qizhi Tang; Flavio Vincenti
Journal:  J Clin Invest       Date:  2017-06-30       Impact factor: 14.808

Review 5.  Translational impact of NIH-funded nonhuman primate research in transplantation.

Authors:  Stuart J Knechtle; Julia M Shaw; Bernhard J Hering; Kristy Kraemer; Joren C Madsen
Journal:  Sci Transl Med       Date:  2019-07-10       Impact factor: 17.956

6.  The Pursuit of Regulatory T Cells in the Induction of Transplant Tolerance.

Authors:  Preston R Arnold; Xian C Li
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Regulatory T Cell Therapy for Ischemic Stroke: how far from Clinical Translation?

Authors:  Yuguo Xia; Wei Cai; Angus W Thomson; Xiaoming Hu
Journal:  Transl Stroke Res       Date:  2016-06-16       Impact factor: 6.829

8.  Decreased regulatory T-cell frequency and interleukin-35 levels in patients with rheumatoid arthritis.

Authors:  Xia Zhang; Xiaolu Zhang; Lili Zhuang; Cangcang Xu; Tao Li; Guili Zhang; Ying Liu
Journal:  Exp Ther Med       Date:  2018-10-19       Impact factor: 2.447

9.  Regulatory T Cell Infusion Can Enhance Memory T Cell and Alloantibody Responses in Lymphodepleted Nonhuman Primate Heart Allograft Recipients.

Authors:  M B Ezzelarab; H Zhang; H Guo; L Lu; A F Zahorchak; R W Wiseman; M A Nalesnik; J K Bhama; D K C Cooper; A W Thomson
Journal:  Am J Transplant       Date:  2016-03-17       Impact factor: 8.086

10.  Combined GM-CSF and G-CSF administration mobilizes CD4+ CD25hi Foxp3hi Treg in leukapheresis products of rhesus monkeys.

Authors:  Kazuki Sasaki; Yu-Chao Wang; Lien Lu; Julia Hughes; Veronica Vujevich; Angus W Thomson; Mohamed B Ezzelarab
Journal:  Am J Transplant       Date:  2020-01-20       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.